Use of sodium-glucose cotransporter-2 inhibitors in France: Analysis of French nationwide health insurance database - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Diabetes, Obesity and Metabolism Année : 2024

Use of sodium-glucose cotransporter-2 inhibitors in France: Analysis of French nationwide health insurance database

Résumé

AIM: Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) have been commercialized in France for type 2 diabetes since April 2020 and later for heart and renal diseases. Given the recent developments in treating diabetes and the widening of SGLT-2i indications, we aimed to study changes in the use of glucose-lowering drugs in France and to characterize SGLT-2i new users. METHODS: We performed a nationwide utilization study using the French health insurance database. Trends in incidence and prevalence of glucose-lowering drug use were assessed by a repeated cross-sectional study in 2019 and 2021. A cohort study of incident SGLT-2i users was then conducted to describe patient characteristics and the strategy for treating diabetes. RESULTS: The prevalence of SGLT-2i use gradually reached 0.1% in the third quarter of 2021 and increased more significantly to 0.2% thereafter. SGLT-2i became the second most prescribed glucose-lowering drug class after metformin at the end of 2021 (0.1%). Among the cohort of 125 387 SGLT-2i new users (mean age 65.0 years; 60.1% of men), 87.6% presented a diabetic comorbidity. The patient profile changed over the study period with an increasing proportion of patients with cardiovascular (28.7% in 2020 vs. 40.2% in 2021) or renal (7.7% in 2020 vs. 11.8% in 2021) comorbidities at initiation. The main combinations used at SGLT-2i initiation were metformin (12.5%) and metformin plus dipeptidyl peptidase-4 inhibitors (8.1%). One-year probability of SGLT-2i persistence was estimated to be 55%. CONCLUSION: The expansion of indications for SGLT-2i and the broadening of the target population make it essential to assess the reasons for discontinuation and review their safety profile.
Fichier principal
Vignette du fichier
BPH_DiabetesObesMetab_2024_Germay.pdf (1.09 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04471475 , version 1 (21-02-2024)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

Citer

Sibylle de Germay, Elodie Pambrun, Antoine Pariente, Guillaume Grenet, Julien Bezin, et al.. Use of sodium-glucose cotransporter-2 inhibitors in France: Analysis of French nationwide health insurance database. Diabetes, Obesity and Metabolism, 2024, ⟨10.1111/dom.15472⟩. ⟨hal-04471475⟩

Collections

U1219
6 Consultations
3 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More